0001567619-22-022055.txt : 20221228 0001567619-22-022055.hdr.sgml : 20221228 20221228082256 ACCESSION NUMBER: 0001567619-22-022055 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221223 FILED AS OF DATE: 20221228 DATE AS OF CHANGE: 20221228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ALSTODT LANCE CENTRAL INDEX KEY: 0001756228 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37603 FILM NUMBER: 221491664 MAIL ADDRESS: STREET 1: BIORESTORATIVE THERAPIES, INC. STREET 2: 40 MARCUS DRIVE, SUITE 1 CITY: MELVILLE STATE: NY ZIP: 11747 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BioRestorative Therapies, Inc. CENTRAL INDEX KEY: 0001505497 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 911835664 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 MARCUS DRIVE CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: (631) 760-8100 MAIL ADDRESS: STREET 1: 40 MARCUS DRIVE CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: Stem Cell Assurance, Inc. DATE OF NAME CHANGE: 20101110 4 1 doc1.xml FORM 4 X0306 4 2022-12-23 0 0001505497 BioRestorative Therapies, Inc. BRTX 0001756228 ALSTODT LANCE C/O BIORESTORATIVE THERAPIES, INC. 40 MARCUS DRIVE, SUITE 1 MELVILLE NY 11747 1 1 0 0 President, CEO, COB Common Stock 2022-12-23 4 P 0 200 3.02 A 185921 D Common Stock 2022-12-23 4 P 0 100 2.99 A 186021 D Stock Option 5.08 2031-03-18 Common Stock 293479 293479 D Stock Option 5.08 2031-11-04 Common Stock 42059 42059 D Includes 100,935 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,036 shares on January 18, 2023, 1,037 shares on February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 with the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested. The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022. /s/ Lance Alstodt 2022-12-27